Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer DiseaseEdmond Teng, Carlo de Lena, Nawaf Yassi et al.|JAMA Neurology|2022Cited by 188
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: LaurietCecília Monteiro, William Alvin McElveen, Balázs István Tóth et al.|Neurology|2023Cited by 104
Cross-sectional associations between [18F]GTP1 tau PET and cognition in Alzheimer's diseaseEdmond Teng, Robby M. Weimer, Michael E. Ward et al.|Neurobiology of Aging|2019Cited by 46
Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s diseaseEdmond Teng, Robby M. Weimer, Paul T. Manser et al.|Alzheimer s Research & Therapy|2021Cited by 33
O3‐14‐02: TAU BURDEN MEASURED USING [18F]GTP1 CORRELATES WITH CSF TAU PHOSPHORYLATION AT SITES T217 AND T205 MORE CLOSELY THAN T181Kristin R. Wildsmith, Robby M. Weimer, Nicolas R. Barthélemy et al.|Alzheimer s & Dementia|2018Cited by 4